Citius Pharmaceuticals, Inc. (CTXR): Price and Financial Metrics
CTXR Price/Volume Stats
| Current price | $1.53 | 52-week high | $26.25 |
| Prev. close | $1.60 | 52-week low | $0.65 |
| Day low | $1.52 | Volume | 513,600 |
| Day high | $1.67 | Avg. volume | 1,340,117 |
| 50-day MA | $1.14 | Dividend yield | N/A |
| 200-day MA | $0.00 | Market Cap | 16.27M |
CTXR Stock Price Chart Interactive Chart >
Citius Pharmaceuticals, Inc. (CTXR) Company Bio
Citius Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes critical care products. It primarily focuses on developing anti-infective, cancer care, prescription, and mesenchymal stem cell therapy products. The company is developing Mino-Lok, an antibiotic lock solution used to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase III clinical trials; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. Citius Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Cranford, New Jersey.
CTXR Price Returns
| 1-mo | 67.65% |
| 3-mo | N/A |
| 6-mo | -53.64% |
| 1-year | -92.60% |
| 3-year | -93.12% |
| 5-year | -95.85% |
| YTD | -61.75% |
| 2024 | -78.85% |
| 2023 | -4.24% |
| 2022 | -48.70% |
| 2021 | 50.98% |
| 2020 | 0.00% |
Loading social stream, please wait...